Ono Pharmaceutical Co., Ltd.
Records under this name other than the patents Ono Pharmaceutical Co., Ltd. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 89 patents it holds.
Back to Ono Pharmaceutical Co., Ltd.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,441,655 | Monoclonal Antibodies to Programmed Death 1 (PD-1) now held by E. R. Squibb & Sons, L.L.C. In force · High confidence | In force | High confidence | |
| US 8,779,105 | Monoclonal Antibodies to Programmed Death 1 (PD-1) now held by E. R. Squibb & Sons, L.L.C. In force · High confidence | In force | High confidence | |
| US 8,008,449 | Human Monoclonal Antibodies to Programmed Death 1(PD-1) and Methods for Treating Cancer Using ANTI-PD-1 Antibodies Alone or in Combination with Other Immunotherapeutics now held by E. R. Squibb & Sons, L.L.C. In force · High confidence | In force | High confidence | |
| US 12,186,392 | Combination Therapy of an Anti CD20 Antibody with a BTK Inhibitor now held by Hoffmann-La Roche Inc. In force · High confidence | In force | High confidence | |
| US 11,215,607 | Biomarker for Diagnosis of Irritable Bowel Syndrome now held by Tohoku University In force · High confidence | In force | High confidence | |
| US 10,617,667 | Method for Treating Brain Tumors now held by The Regents of the University of California In force · High confidence | In force | High confidence | |
| US 11,572,393 | HMGN Partial Peptide and Cancer Therapy Using the Same now held by Tokyo University of Science Foundation In force · High confidence | In force | High confidence | |
| US 12,036,204 | Pharmaceutical Composition for Treating Tumor now held by Eisai R&D Management Co., Ltd. In force · Low confidence | In force | Low confidence | |
| US 12,122,846 | Chimeric Antigen Receptor for Tumor Targeting now held by Fate Therapeutics, Inc. In force · High confidence | In force | High confidence | |
| US 9,387,247 | Monoclonal Antibodies to Programmed Death 1 (PD-1) now held by E. R. Squibb & Sons, L.L.C. Term ended Term ended Oct 24, 2026 · High confidence | Term ended | Term ended Oct 24, 2026 | High confidence |